Sarcoma  >>  AiRuiKa (camrelizumab)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AiRuiKa (camrelizumab) / HLB Bio Group
ChiCTR2100044810: A controlled clinical study the combination of first-line immunotherapy and targeted therapy for advanced sarcomatoid renal cell carcinoma

Recruiting
4
40
 
camrelizumab plus Pazopanib Tablets ;Pazopanib Tablets
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Partially self-financing
Advanced sarcomatoid renal cell carcinoma
 
 
ChiCTR2100049974: An exploratory clinical study of Camrelizumab combined with AD chemotherapy in the first-line treatment of metastatic or inoperable undifferentiated pleomorphic sarcoma (UPS)

Not yet recruiting
4
30
 
Drug intervention
Peking University Cancer Hospital; Peking University Cancer Hospital, NA
undifferentiated pleomorphic sarcoma
 
 
ChiCTR2100052825: Phase II clinical studies of single center, open, single arm of paclitaxel (albumin binding) in combination with camrelizumab second line and above line treatment of metastatic/locally unresectable soft tissue sarcoma

Not yet recruiting
4
40
 
Camrelizumab and chemotherapy
He'nan Tumor Hospital; He'nan Tumor Hospital, Self-funded
Soft tissue sarcoma
 
 

Download Options